Immunomodulatory treatments for multiple sclerosis: Lessons from direct comparative studies;Traitements de fond de la sclérose en plaques: Enseignements des études randomisées comparatives directes

Revue Neurologique

Volumn 166, Issue 1, 2010, Pages 21-31

  Ouallet, J C ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Comparative clinical trials; Glatiramer acetate; Interferon ; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; PLACEBO;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW;

ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON TYPE I, RECOMBINANT; INTERFERONS; MULTIPLE SCLEROSIS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 76349097974     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2009.05.006     Document Type: Review

References (35)

1. P.A. Brex, O. Ciccarelli, J.I. O'Riordan, M. Sailer, A.J. Thompson, and D.H. Miller A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 346 2002 158 164 (Pubitemid 34438881)
2. D. Cadavid, L. Wolansky, S. Cook, J. Halper, J. Hill, M. Younes, et al. Betaseron versus copaxone in multiple sclerosis with triple-dose gadolinium and 3 Tesla MRI Endpoints (BECOME): announcement of secondary clinical outcomes Mult Scler 13 2007 P207
3. M. Clanet, E.W. Radue, L. Kappos, H.P. Hartung, R. Hohlfeld, and M. Sandberg-Wollheim A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS Neurology 59 2002 1507 1517 (Pubitemid 35387054)
4. G. Comi, J. Cohen, and M. Filippi Results from a phase III, one-year, randomized, double-blind, parallel-group, dose comparison study with glatiramer acetate in relapsing-remitting multiple sclerosis Mult Scler 14 2008 S299 S301
5. G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan, and O. Fernandez Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study Lancet 357 2001 1576 1582 (Pubitemid 32488815)
6. G. Comi, M. Filippi, and J.S. Wolinsky European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group Ann Neurol 49 2001 290 297 (Pubitemid 32202781)
7. Comi G, PreCISe STudy Group. Early glatiramer acetate treatment in delaying conversion to clinically definite multiple sclerosis (CDMS) in subjects presenting with a clinically isolated syndrome. Neurology 2008;70: Late Breaking Science (Suppl):9.
8. L. Durelli, E. Verdun, P. Barbero, M. Bergui, E. Versino, and A. Ghezzi Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) Lancet 359 2002 1453 1460 (Pubitemid 34457761)
9. G. Edan, D. Miller, M. Clanet, C. Confavreux, O. Lyon-Caen, and C. Lubetzki Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria J Neurol Neurosurg Psychiatry 62 1997 112 118 (Pubitemid 27090928)
10. G. Edan, G. Comi, C. Lebrun, D. Brassat, C. Lubetzki, B. Stankoff, et al. The French-Italian Mitoxantrone-Interferon-beta Trial: a 3-year randomised study Mult Scler 13 Suppl. 2 2007
11. B. Engelhardt, and L. Kappos Natalizumab: targeting alpha4-integrins in multiple sclerosis Neurodegener Dis 5 2008 16 22 (Pubitemid 350261811)
12. L.K. Fisniku, P.A. Brex, D.R. Altmann, K.A. Miszkiel, C.E. Benton, and R. Lanyon Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis Brain 131 2008 808 817 (Pubitemid 351294716)
13. E.J. Fox Mechanism of action of mitoxantrone Neurology 63 2004 S15 S18
14. M.S. Freedman, G.S. Francis, E.A. Sanders, G.P. Rice, P. O'Connor, and G. Comi Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study Mult Scler 11 2005 41 45 (Pubitemid 40259973)
15. L.D. Jacobs, R.W. Beck, J.H. Simon, R.P. Kinkel, C.M. Brownscheidle, T.J. Murray, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group N Engl J Med 343 2000 898 904
16. L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.M. Herndon, J.R. Richert, A.M. Salazar, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39 1996 285 294
17. K.P. Johnson, B.R. Brooks, J.A. Cohen, C.C. Ford, J. Goldstein, R.P. Lisak, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268 1276
18. L. Kappos, C.H. Polman, M.S. Freedman, G. Edan, H.P. Hartung, and D.H. Miller Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249 (Pubitemid 44563835)
19. O.A. Khan, A.C. Tselis, J.A. Kamholz, J.Y. Garbern, R.A. Lewis, and R.P. Lisak A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing - remitting multiple sclerosis: results after 18 months of therapy Mult Scler 7 2001 349 353 (Pubitemid 33138343)
20. N. Koch-Henriksen, P.S. Sorensen, T. Christensen, J. Frederiksen, M. Ravnborg, and K. Jensen A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis Neurology 66 2006 1056 1060 (Pubitemid 44044791)
21. E. Le Page, E. Leray, G. Taurin, M. Coustans, J. Chaperon, S.P. Morrissey, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients J Neurol Neurosurg Psychiatry 79 2008 52 56
22. C.E. Markowitz Interferon-beta: mechanism of action and dosing issues Neurology 68 2007 S8 11
23. D.D. Mikol, F. Barkhof, P. Chang, P.K. Coyle, D.R. Jeffery, S.R. Schwid, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Lancet Neurol 7 2008 903 904
24. O'Connor P, Arnason B, Comi G, Filippi M, Cook S, Goodin D, et al. Interferon beta-1b 500 mcg, interferon beta-1b 250mcg and glatiramer acetate: primary outcomes of the Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose) study. Neurology 2008; 70:(Late Breaking Science Suppl.):4.
25. H. Panitch, D.S. Goodin, G. Francis, P. Chang, P.K. Coyle, and P. O'Connor Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial Neurology 59 2002 1496 1506 (Pubitemid 35387053)
26. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
27. J. Ramtahal, A. Jacob, K. Das, and M. Boggild Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis J Neurol 253 2006 1160 1164 (Pubitemid 44511472)
28. R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, and E.W. Radue Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 2006 911 923 (Pubitemid 43313658)
29. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61.
30. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
31. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999;53:679-86.
32. M. Tintoré Rationale for early intervention with immunomodulatory treatments J Neurol 255 Suppl. 1 2008 37 43 (Pubitemid 351341871)
33. US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Baltimore, MD: Williams and Wilkins; 1996.
34. M.S. Weber, R. Hohlfeld, and S.S. Zamvil Mechanism of action of glatiramer acetate in treatment of multiple sclerosis Neurotherapeutics 4 2007 647 653 (Pubitemid 47499292)
35. L. Wolansky, S. Cook, J. Skurnick, J. Lincoln, K. Tulloch, P. Franco, et al. Betaseron vs Copaxone in MS with triple-dose gadolinium and 3-T MRI Endpoints (BECOME): announcement of final primary study outcome Mult Scler 13 2007 P207